Thats the crap that needs to stop .. The April
Post# of 148174
The April 15th PR stated that Cytodyne would perform an interim analysis on the Phase 2b/3 trial data from 50 patients. Today NP mentioned that (per the FDA,?) the interim analysis would be at 50% enrollment (~190 patients).
Read More: https://investorshangout.com/post/view?id=582...z6Rix7tklz